Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin–Activin–Follistatin–IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study

Diabetes Research and Clinical Practice 2026

View at publisher
Authors: Valeria Gutierrez de Piñeres, Arantxa Ramirez-Cisneros, Claudia Sofía Tamayo-Torres, Angeliki M. Angelidi, Marianthi Kavelidou, Konstantinos Stefanakis, Christos S. Mantzoros
DOI: 10.1016/j.diabres.2026.113113
Cited by: 2
References: 27

Fields of Study & Subjects

Growth Hormone and Insulin-like Growth Factors Muscle Physiology and Disorders Adipose Tissue and Metabolism

Publication details

Journal / source
Diabetes Research and Clinical Practice
Publisher
Elsevier BV
Volume
233
Pages
113113–113113
Publication date
20 January 2026
Language
EN